menu
    • menu
    [{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Haystack Oncology \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Cincinnati","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Certepetide","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ University of Cincinnati","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ University of Cincinnati"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Lisata Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Valo Therapeutics \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"WARPNINE","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ WARPNINE","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ WARPNINE"},{"orgOrder":0,"company":"GATC Health","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"GATC Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GATC Health \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GATC Health \/ Lisata Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Certepetide

    Menu

    Certepetide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GATC Health

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            GATC Health

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Lisata Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lisata, GATC Use AI to Derisk and Accelerate Drug Development

                            Details : GATC’s MAT AI platform will analyze Lisata’s investigational drug, LSTA1 (certepetide), to identify optimized and derisked development opportunities across various indications.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            March 05, 2025

                            Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Lisata Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Durvalumab,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : WARPNINE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lisata and WARPNINE Report Preliminary Results from Phase 1b/2a iLSTA Trial

                            Details : CEND-1 (certepetide) is an Alpha-V integrin inhibitor peptide candidiate which is being evaluated in combination with chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Certepetide,Durvalumab,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : WARPNINE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lisata Reports Positive Preliminary Data from ASCEND Trial in Pancreatic Cancer

                            Details : CEND-1 (certepetide) is an Alpha-V integrin inhibitor peptide candidiate which is being evaluated in combination with chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Valo Therapeutics

                            United Kingdom arrow
                            euroPLX 87
                            Not Confirmed

                            Valo Therapeutics

                            United Kingdom arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lisata Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

                            Details : The collaboration aims to investigate the benefits of combining Lisata's, LSTA1 (certepetide), with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            November 06, 2024

                            Lead Product(s) : Certepetide,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lisata Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Bevacizumab

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Discovery

                            Sponsor : University of Cincinnati

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lisata And Cincinnati University to Research Certepetide for Endometriosis

                            Details : Through the agreement, Lisata will evaluate a novel cyclic peptide product candidate, LSTA1 (certepetide), in combination with bevacizumab to treat endometriosis.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Certepetide,Bevacizumab

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Discovery

                            Sponsor : University of Cincinnati

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lisata Treats First Patient in Second-Line Cholangiocarcinoma BOLSTER Trial

                            Details : LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of second-line cholangiocarcinoma.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            September 17, 2024

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lisata’s Certepetide Receives FDA Orphan Drug Designation for Cholangiocarcinoma

                            Details : LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of cholangiocarcinoma.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            September 05, 2024

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Haystack Oncology

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Haystack Oncology

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Panitumumab,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Lisata Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Haystack Oncology and Lisata Therapeutics Start Collaboration to Use MRD™ Tech

                            Details : Through the collaboration, Lisata will utilize MRD technology to detect ctDNA in a clinical trial evaluating CEND-1 (certepetide) combined with chemotherapy for the treatment of pancreatic cancer.

                            Product Name : CEND-1

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            July 18, 2024

                            Lead Product(s) : Certepetide,Panitumumab,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Lisata Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lisata Therapeutics Completes Enrollment in Phase 2a BOLSTER Trial of Certepetide

                            Details : LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of cholangiocarcinoma.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            July 16, 2024

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            euroPLX 87
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lisata Therapeutics’ Certepetide Shows Promise in Cholangiocarcinoma in Preclinical Model

                            Details : LSTA1 (certepetide) is an integrin alpha-V antagonist peptide drug candidate, which is being evaluated in preclinical models for the treatment of Intrahepatic Cholangiocarcinoma.

                            Product Name : LSTA1

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            July 10, 2024

                            Lead Product(s) : Certepetide,Durvalumab,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth